Successful treatment of severe menorrhagia at menarche with recombinant factor VIIa in an adolescent girl with type III von Willebrand's disease


Gokcebay D. G. , Culha V., Yarali N. , Ozbek N. Y.

Blood Coagulation and Fibrinolysis, vol.29, no.5, pp.469-471, 2018 (Journal Indexed in SCI Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 29 Issue: 5
  • Publication Date: 2018
  • Doi Number: 10.1097/mbc.0000000000000739
  • Title of Journal : Blood Coagulation and Fibrinolysis
  • Page Numbers: pp.469-471
  • Keywords: menorrhagia, recombinant factor VIIa, von Willebrand's disease

Abstract

© 2018 Wolters Kluwer Health, Inc.Type III von Willebrand's disease (vWD) is an inherited bleeding disorder, which is frequently associated with menorrhagia in women. Treatment options include antifibrinolytics, desmopressin, von Willebrand factor/factor VIII concentrates and in intractable bleeding circumstances recombinant factor VIIa (rFVIIa). We present an adolescent case with type III vWD who had a menorrhagia at menarche that was refractory to the standard treatment and ultimately was treated with rFVIIa successfully.